NASDAQ:APLS Apellis Pharmaceuticals - APLS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $66.18 +1.20 (+1.85%) (As of 03/29/2023 12:00 AM ET) Add Compare Share Share Today's Range$65.26▼$66.7150-Day Range$50.49▼$66.9652-Week Range$33.32▼$70.75Volume1.14 million shsAverage Volume1.68 million shsMarket Capitalization$7.37 billionP/E RatioN/ADividend YieldN/APrice Target$78.40 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Apellis Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.64 Rating ScoreUpside/Downside18.5% Upside$78.40 Price TargetShort InterestBearish10.92% of Shares Sold ShortDividend StrengthN/ASustainability-1.27Upright™ Environmental ScoreNews Sentiment0.57Based on 7 Articles This WeekInsider TradingSelling Shares$4.99 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.15) to ($3.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.11 out of 5 starsMedical Sector500th out of 999 stocksPharmaceutical Preparations Industry237th out of 489 stocks 3.3 Analyst's Opinion Consensus RatingApellis Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.64, and is based on 8 buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $78.40, Apellis Pharmaceuticals has a forecasted upside of 18.5% from its current price of $66.18.Amount of Analyst CoverageApellis Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.92% of the outstanding shares of Apellis Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverApellis Pharmaceuticals has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Apellis Pharmaceuticals has recently increased by 13.13%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldApellis Pharmaceuticals does not currently pay a dividend.Dividend GrowthApellis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreApellis Pharmaceuticals has received a 67.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for deficiency diseases", "Pegcetacoplan", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Apellis Pharmaceuticals is -1.27. Previous Next 2.0 News and Social Media Coverage News SentimentApellis Pharmaceuticals has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Apellis Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 29 people have searched for APLS on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Apellis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Apellis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,991,862.00 in company stock.Percentage Held by InsidersOnly 8.00% of the stock of Apellis Pharmaceuticals is held by insiders.Percentage Held by Institutions87.26% of the stock of Apellis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Apellis Pharmaceuticals are expected to grow in the coming year, from ($5.15) to ($3.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apellis Pharmaceuticals is -10.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apellis Pharmaceuticals is -10.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApellis Pharmaceuticals has a P/B Ratio of 42.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Apellis Pharmaceuticals (NASDAQ:APLS) StockApellis Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.Read More Receive APLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address APLS Stock News HeadlinesMarch 26, 2023 | americanbankingnews.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Sells $1,882,200.00 in StockMarch 23, 2023 | americanbankingnews.comAlec Machiels Sells 1,250 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) StockMarch 30, 2023 | Investing Daily (Ad)A 100% Win Rate In 2022…The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. March 16, 2023 | msn.comApellis Pharmaceuticals' Empaveli sNDA action date extended by FDAFebruary 27, 2023 | finance.yahoo.comApellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional SharesFebruary 22, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Medtronic (MDT), Crispr Therapeutics AG (CRSP) and Apellis Pharmaceuticals (APLS)February 22, 2023 | finance.yahoo.comWhen Will Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Become Profitable?February 22, 2023 | finance.yahoo.comApellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsMarch 30, 2023 | The Oxford Club (Ad)Unusual Passive Income Investment (Found on a Golf Course)Marc reveals how anyone can get into a similar opportunity for just $5.February 20, 2023 | finance.yahoo.comAnalysts Estimate Apellis Pharmaceuticals, Inc. (APLS) to Report a Decline in Earnings: What to Look Out forFebruary 18, 2023 | marketwatch.comStocks to Watch: Apellis Pharmaceuticals, Sigma LithiumFebruary 16, 2023 | nasdaq.comAvoro Capital Advisors Now Owns 9.60% of Apellis Pharmaceuticals (APLS)December 16, 2022 | finance.yahoo.comApellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic AtrophyDecember 7, 2022 | finance.yahoo.comApellis Pharmaceuticals, Inc. (APLS) Down 0.5% Since Last Earnings Report: Can It Rebound?November 29, 2022 | barrons.comPremarket Movers: Elbit Systems, CME Group Cl A, Apellis PharmaceuticalsNovember 18, 2022 | benzinga.comLooking At Apellis Pharmaceuticals's Recent Unusual Options ActivityNovember 18, 2022 | marketwatch.comApellis Shares Jump Premarket as FDA Accepts Amendment >APLSNovember 18, 2022 | markets.businessinsider.comApellis : FDA Accepts Pegcetacoplan NDA Amendment For Geographic Atrophy; Stock UpNovember 18, 2022 | finance.yahoo.comApellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)November 8, 2022 | markets.businessinsider.com5 Analysts Have This to Say About Apellis PharmaceuticalsOctober 16, 2022 | seekingalpha.comCiti lists four more value-creating events in biotech for this yearOctober 12, 2022 | finance.yahoo.comCorcept (CORT) Begins Phase II Study on Dazucorilant for ALSOctober 3, 2022 | finance.yahoo.comWhy Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers TodaySeptember 8, 2022 | markets.businessinsider.comStifel Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To KnowSeptember 7, 2022 | seekingalpha.comIveric bio: Further Upside Possible Based On Expanded Opportunities With ZimuraSeptember 1, 2022 | finance.yahoo.comApellis's Pegcetacoplan Shows Increased Effects In Geographic Atrophy At Two YearsAugust 24, 2022 | msn.comApellis Shares Show Mixed Reaction After Positive 2 Years Data From Late-Stage Retinal Disorder StudySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive APLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address APLS Company Calendar Last Earnings2/21/2023Today3/30/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APLS CUSIPN/A CIK1492422 Webwww.apellis.com Phone(617) 977-5700FaxN/AEmployees476Year Founded2009Price Target and Rating Average Stock Price Forecast$78.40 High Stock Price Forecast$139.00 Low Stock Price Forecast$40.00 Forecasted Upside/Downside+18.5%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($6.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-652,170,000.00 Net Margins-864.70% Pretax Margin-863.81% Return on Equity-204.77% Return on Assets-68.99% Debt Debt-to-Equity Ratio0.55 Current Ratio4.29 Quick Ratio3.78 Sales & Book Value Annual Sales$75.42 million Price / Sales97.65 Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / Book42.97Miscellaneous Outstanding Shares111,291,000Free Float102,388,000Market Cap$7.37 billion OptionableNot Optionable Beta1.19 Social Links Key ExecutivesCedric FrancoisPresident, Chief Executive Officer & DirectorNur NicholsonChief Technical Operations OfficerTimothy Eugene SullivanChief Financial Officer & TreasurerPascal DeschateletsChief Scientific OfficerLukas ScheiblerChief Research OfficerKey CompetitorsLegend BiotechNASDAQ:LEGNAscendis Pharma A/SNASDAQ:ASNDKaruna TherapeuticsNASDAQ:KRTXRoivant SciencesNASDAQ:ROIVOrganon & Co.NYSE:OGNView All CompetitorsInsiders & InstitutionsCedric FrancoisSold 30,000 sharesTotal: $1.88 M ($62.74/share)Alec MachielsSold 1,250 sharesTotal: $80,037.50 ($64.03/share)Victory Capital Management Inc.Sold 242,500 shares on 3/10/2023Ownership: 0.387%Pascal DeschateletsSold 12,000 sharesTotal: $765,480.00 ($63.79/share)Voya Investment Management LLCSold 7,253 shares on 2/28/2023Ownership: 0.142%View All Insider TransactionsView All Institutional Transactions APLS Stock - Frequently Asked Questions Should I buy or sell Apellis Pharmaceuticals stock right now? 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APLS shares. View APLS analyst ratings or view top-rated stocks. What is Apellis Pharmaceuticals' stock price forecast for 2023? 14 analysts have issued twelve-month price targets for Apellis Pharmaceuticals' shares. Their APLS share price forecasts range from $40.00 to $139.00. On average, they expect the company's share price to reach $78.40 in the next year. This suggests a possible upside of 18.5% from the stock's current price. View analysts price targets for APLS or view top-rated stocks among Wall Street analysts. How have APLS shares performed in 2023? Apellis Pharmaceuticals' stock was trading at $51.71 at the start of the year. Since then, APLS stock has increased by 28.0% and is now trading at $66.18. View the best growth stocks for 2023 here. Are investors shorting Apellis Pharmaceuticals? Apellis Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 12,150,000 shares, an increase of 13.1% from the February 28th total of 10,740,000 shares. Based on an average trading volume of 1,600,000 shares, the days-to-cover ratio is presently 7.6 days. View Apellis Pharmaceuticals' Short Interest. When is Apellis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our APLS earnings forecast. How were Apellis Pharmaceuticals' earnings last quarter? Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) released its quarterly earnings data on Tuesday, February, 21st. The company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.45) by $0.05. The firm earned $22.70 million during the quarter, compared to the consensus estimate of $24.44 million. Apellis Pharmaceuticals had a negative trailing twelve-month return on equity of 204.77% and a negative net margin of 864.70%. The business's quarterly revenue was down 62.4% compared to the same quarter last year. What ETFs hold Apellis Pharmaceuticals' stock? ETFs with the largest weight of Apellis Pharmaceuticals (NASDAQ:APLS) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC), First Trust Innovation Leaders ETF (ILDR), Harbor Health Care ETF (MEDI), SPDR S&P Biotech ETF (XBI), Jacob Forward ETF (JFWD), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Invesco Nasdaq Biotechnology ETF (IBBQ). What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO? 18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend. What other stocks do shareholders of Apellis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI). When did Apellis Pharmaceuticals IPO? (APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO. What is Apellis Pharmaceuticals' stock symbol? Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS." Who are Apellis Pharmaceuticals' major shareholders? Apellis Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Avoro Capital Advisors LLC (9.61%), T. Rowe Price Investment Management Inc. (5.28%), Price T Rowe Associates Inc. MD (2.49%), Jennison Associates LLC (2.27%), Geode Capital Management LLC (1.58%) and Boxer Capital LLC (1.43%). Insiders that own company stock include A Sinclair Dunlop, Adam J Townsend, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Jeffrey Eisele, Karen Lewis, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Pascal Deschatelets, Victoria L Brown and Victoria L Brown. View institutional ownership trends. How do I buy shares of Apellis Pharmaceuticals? Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Apellis Pharmaceuticals' stock price today? One share of APLS stock can currently be purchased for approximately $66.18. How much money does Apellis Pharmaceuticals make? Apellis Pharmaceuticals (NASDAQ:APLS) has a market capitalization of $7.37 billion and generates $75.42 million in revenue each year. The company earns $-652,170,000.00 in net income (profit) each year or ($6.13) on an earnings per share basis. How many employees does Apellis Pharmaceuticals have? The company employs 476 workers across the globe. Does Apellis Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Apellis Pharmaceuticals: APL DEL Holdings II LLC, APL DEL Holdings LLC, APL PRG I Corp., APL Sales I LLC, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., Apellis MA Securities Inc., Apellis Netherlands B.V., Apellis Switzerland GmbH, Apellis U.K. Limited, and Potentia Pharmaceuticals.Read More How can I contact Apellis Pharmaceuticals? Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The official website for the company is www.apellis.com. The company can be reached via phone at (617) 977-5700 or via email at investors@apellis.com. This page (NASDAQ:APLS) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.